This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are “material information” as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.

2. The term “Issuer” includes the Issuer and any of its subsidiaries.

3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer continued its business of developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor, and assess treatment for cancer early, accurately and cost effectively. The Company continues to hold regular management meetings regarding all aspects of the Company’s business plan and executes action items that result from these meetings.

Management’s primary areas of focus continue to include:

• Accelerating commercialization efforts of its early lung cancer lab developed test (LDT) following promising interim data presented at European Society of Medical Oncology in Paris France on Sept 10^th. The data was derived on an independent large scale retrospective study with expanded control. The results were statistically significant and generated interest from leading institutions across Europe, India and S. America which the company is actively pursuing.

• Preparation for lab certification and accreditation to meet both the Canadian and European ISO 15189 standard but also US based CLIA and CAP approvals to provide lab services internationally.

• Engage with USA medical institutions, insurance companies (payers) regulatory experts and bio-pharma partners as it’s early lung cancer LDT commercialization efforts gather momentum. US market is strategic due to its large addressable lung cancer screening market for at risk population (Over 16 million annually)

• Seek additional non-dilutive funding resources for its lab operations, certification of its clinical lab, U.S. expansion and clinical studies.

2. Provide a general overview and discussion of the activities of management.

• Beyond covid worriers, businesses are currently facing strong inflationary headwinds, supply chain bottlenecks and labour shortages. Management is taking measures to counteract any negative impact of these factors after managing the Covid challenges over the past 3 years by instituting resilient operational and financial systems/processes.

• BioMark has changed its auditors from PricewaterhouseCoopers LLP (“Former Auditor”) to MNP LLP (“Successor Auditor”). The Former Auditor resigned as the auditor of the Company effective November 3^rd, 2022, and the board of directors of the Company appointed the Successor Auditor effective as of the same date, until the next Annual General Meeting of the Company.

• BioMark completed successful discussions with interested Brazilian parties. The parties included head clinicians and lab technicians from the leading hospital that offers advanced diagnostic services. In addition, team from the largest CRO were later engaged to establish the most viable market entry and development plans for the domestic Brazil market. More in depth discussions are still underway.

• On November 16^th, 2022, Notice of Meeting, Form of Proxy and Management Information Circular related to 2022 Annual General Meeting were filed on SEDAR as required by regulators.

• On November 22, 2022, BioMark signed a collaborative research agreement between Delhi Institute of Pharmaceutical Sciences and Research (DPSRU) in New Delhi, India, and St. Boniface Research Centre (SBRC) in Winnipeg, Manitoba for potential early lung cancer detection for the population in India. This would be critical for India as lung cancer cases are projected to increase by five- to seven-fold between 2025 to 2030 due to pollution and climate change.

• Conducted and completed quarter filing – Unaudited Financial Statement and MD&A filed in SEDAR and Canadian Securities Exchange as required by regulators. On November 28, 2022, BioMark provided financial results and highlights for the second quarter ended September 30, 2022, and operational updates. The Company also announced that it amended the term of 1,15,579 non-broker warrants (the “Warrants”) issued in relation to a private placement financing that closed on December 13, 2019 and are scheduled to expire on December 13, 2022. The Warrants extended their term by one year such that the warrants will be exercisable until December 13, 2023, at an exercise price per share of C$0.45. All other terms of the warrants will remain unchanged.

• BioMark continue its European expansion with the development of a pilot program for early detection of lung cancer in partnership the French group TransDiag and the Hospices Civils de Lyon (HCL). TransDiag has been successful in attracting other well-known clinical institutions and Gustave Roussy (ranked # 3 globally for oncology research and treatment institution) and L’Institut Curie to partner with BioMark to conduct similar trials that will be useful in assessing, reviewing, and establishing a lung cancer screening platform in Europe, starting in France. On Nov 29th. 2022 BioMark signed an NDA with L’Institut Curie. These are all world leading institutions that were impressed by the data it presented at ESMO in Paris during Sept 9-13^th, 2022.

• BioMark continued to entertain discussions with various financial institutions and government agencies to secure non-dilutive funding, favourable loans, and equity investments to accelerate the commercialization of its early lung cancer liquid biopsy franchise and to advance its expansion strategy in USA and internationally as well as for general corporate purposes.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not applicable.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not applicable.

8. Describe the acquisition of new customers or loss of customers.

Not applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

The Issuer continues to file trademark and patents in specific jurisdictions for all its patents. Review of the filings and opinions from patent offices are being reviewed as needed.

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs.

Not applicable.

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not applicable.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not applicable.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not applicable.

14. Provide details of any securities issued and options or warrants granted.

On November 28, The Company amended the term of 1,15,579 non-broker warrants (the “Warrants”) issued in relation to a private placement financing that closed on December 13, 2019 and are scheduled to expire on December 13, 2022. The Warrants extended their term by one year such that the warrants will be exercisable until December 13, 2023, at an exercise price per share of C$0.45. All other terms of the warrants will remain unchanged.

15. Provide details of any loans to or by Related Persons.

Not applicable.

16. Provide details of any changes in directors, officers, or committee members.

Not applicable.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are discussed in the Form 51-102F1 Management’s Discussion & Analysis Annual Report for the Year Ended March 31, 2022.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there where is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).

4. All of the information in this Form 7 Monthly Progress Report is true.

Dated December 5^th, 2022 .